[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Raghavan D: Progress in the chemotherapy of metastatic cancer of the urinary tract. Cancer; 2003 Apr 15;97(8 Suppl):2050-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress in the chemotherapy of metastatic cancer of the urinary tract.
  • Cytotoxic chemotherapy has an evolving role in the management of metastatic cancer of the bladder and urinary tract.
  • The most responsive of these tumors are transitional cell carcinomas.
  • Standard single agents (e.g., methotrexate, doxorubicin, mitomycin, ifosfamide, vinblastine, and cisplatin) have produced objective response rates of 15-25% and combination chemotherapy has resulted in objective regression in 40-75% of cases.
  • Traditional cytotoxic regimens have been ineffective in the management of adenocarcinoma and squamous cell carcinoma of the bladder.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / mortality. Carcinoma, Transitional Cell / secondary. Humans. Randomized Controlled Trials as Topic. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society
  • (PMID = 12673696.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


2. Maezawa T, Yonese J, Tsukamoto T, Ishii N, Fukui I: [Combination chemotherapy with ifosfamide, 5-fuluorouracil, etoposide and cisplatin for advanced urothelial cancer: the treatment results and significance of tumor marker evaluation in response assessment of chemotherapy]. Nihon Hinyokika Gakkai Zasshi; 2002 Nov;93(7):727-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination chemotherapy with ifosfamide, 5-fuluorouracil, etoposide and cisplatin for advanced urothelial cancer: the treatment results and significance of tumor marker evaluation in response assessment of chemotherapy].
  • PURPOSE: We investigated treatment results of IFEPchemotherapy in patients with advanced urothelial cancer (N2-3, M1) and the usefulness of measuring serum CEA, CA19-9 and SCC to evaluate the treatment response of chemotherapy.
  • PATIENTS AND METHODS: From March 1994 to May 2000, we treated 41 patients with IFEP therapy consisting of ifosfamide (2 g/m2), 5-fluorouracil (750 mg/m2), etoposide (100 mg/m2) and cisplatin (20 mg/m2), all of which were given daily for 3 consecutive days every 3 weeks.
  • Before initiating the chemotherapy, serum CEA, CA19-9 and SCC were measured.
  • RESULTS: The response rate of the chemotherapy was 53.7% (CR + PR), with a median survival period being 10.8 months and a median duration of response for the 22 responders being 7.5 months.
  • Bone marrow toxicity was significant with 1 drug-related death.
  • Before chemotherapy, tumor marker was elevated in 19 patients: CEA in 7, CA19-9 in 13 and SCC in 10.
  • Serum levels of the tumor markers were related neither to the primary and metastatic tumor sites nor to patient's survival time.
  • However, decline of serum tumor markers after chemotherapy was well related to response of the tumor assessed by imaging studies.
  • CONCLUSION: IFEP chemotherapy appears to be active in the treatment of advanced urothelial tumor and serial measurement of serum CEA, CA19-9 and SCC may be useful in judgement of tumor response to the chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carcinoma, Transitional Cell / drug therapy. Serpins. Urologic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antigens, Neoplasm / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Cisplatin / administration & dosage. Etoposide / administration & dosage. Evaluation Studies as Topic. Female. Fluorouracil / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12494517.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Serpins; 0 / squamous cell carcinoma-related antigen; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


3. Higano CS, Tangen CM, Sakr WA, Faulkner J, Rivkin SE, Meyers FJ, Hussain M, Baker LH, Russell KJ, Crawford ED, Southwest Oncology Group Trial 8733: Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733. Cancer; 2008 May 15;112(10):2181-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.
  • BACKGROUND: Many patients with invasive urothelial cell cancer are poor candidates for cisplatin-based chemotherapy, and many are high risk for cystectomy.
  • Southwest Oncology Group Trial 8733 was designed to address treatment for such patients.
  • METHODS: Eligible patients had primary or recurrent muscle-invasive disease with transitional cell or squamous cell histology, a performance status from 0 to 2, no extrapelvic disease, a life expectancy >3 months, and adequate hematologic function.
  • CONCLUSIONS: In the current study, the combination of 5-FU and radiation was found to be tolerated well by patients with numerous comorbidities who could not tolerate cisplatin-based therapy or cystectomy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystectomy. Muscle Neoplasms / therapy. Neoadjuvant Therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / therapy. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Carcinoma, Transitional Cell / therapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Prognosis. Survival Rate. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18404692.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA76447
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. De Santis M, Bachner M: New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder. Curr Opin Urol; 2007 Sep;17(5):363-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder.
  • PURPOSE OF REVIEW: To review the systemic treatment, patient selection and treatment outcome of transitional cell carcinoma of the urinary bladder, squamous cell carcinoma and adenocarcinoma, focusing on advances and findings within the last year.
  • RECENT FINDINGS: Cisplatin-based chemotherapy is considered to be the standard treatment for transitional cell carcinoma.
  • In recent updates of randomized trials, patients with favorable prognostic factors were shown to have a chance of long-term disease-free survival even after chemotherapy for metastatic disease.
  • Patient selection for cisplatin, newer drugs or alternative combinations is crucial.
  • New genetic markers like excision repair cross-complementing 1 expression were developed and tested for this purpose.
  • Adequate evaluation of renal function plays an important role for treatment selection, especially in the elderly population.
  • Only few data are available on the systemic treatment of squamous cell carcinoma and adenocarcinoma.
  • Complete resection seems to be more important than chemotherapy in the rare cases of adenocarcinoma of the urinary tract.
  • SUMMARY: In locally advanced and metastatic disease patient- and tumor-related prognostic factors and predictive factors for response to treatment will guide treatment decisions in the future.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Age Factors. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Humans. Neoplasm Metastasis. Patient Selection. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762632.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 58
  •  go-up   go-down


5. Matsumoto S, Nishioka T, Akiyama T, Park YC, Kurita T, Ishikawa Y: [A case of squamous cell carcinoma of the bladder that was successfully treated with multidisciplinary therapies]. Hinyokika Kiyo; 2001 Jan;47(1):43-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell carcinoma of the bladder that was successfully treated with multidisciplinary therapies].
  • Endoscopic examination revealed a disintegration abscess between the bladder neck and prostatic urethra.
  • Transurethral biopsy demonstrated squamous cell carcinoma of the bladder.
  • He received 40 Gy of radiation combined with M-VAC (methotrexate, vinblastine, dovorubicin cisplatin) chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cystectomy. Doxorubicin / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Radiotherapy, Adjuvant. Treatment Outcome. Urethra / surgery. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11235221.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


6. Inui M, Fujita K, Ueda N, Takenaka I, Kakehi Y: [A case of regionally metastatic pure squamous cell carcinoma of the urinary bladder successfully treated with radical chemoradiotherapy]. Hinyokika Kiyo; 2002 Jan;48(1):33-5
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of regionally metastatic pure squamous cell carcinoma of the urinary bladder successfully treated with radical chemoradiotherapy].
  • We report a case of regionally metastatic pure squamous cell carcinoma of the urinary bladder successfully treated with combined radiation and chemotherapy in a 46-year-old man.
  • The patient received 50 Gy external radiation combined with intraarterial and systemic chemotherapy.
  • Pathological complete response was found both in bladder and regional lymph nodes when he underwent radical cystectomy and lymph node dissection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Lymph Nodes / pathology. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Humans. Lymphatic Metastasis. Male. Middle Aged. Peplomycin / administration & dosage. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11868383.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 56H9L80NIZ / Peplomycin; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Kassouf W, Spiess PE, Siefker-Radtke A, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP: Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer; 2007 Aug 15;110(4):764-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience.
  • BACKGROUND: Nonbilharzial squamous cell carcinoma (SCC) of the bladder is a rare entity in the Western hemisphere.
  • Charts were reviewed to assess impact of therapy on survival and patterns of recurrence in those that died of disease.
  • RESULTS: The 2-year overall survival and recurrence-free survival (RFS) rates were 47.6% and 32.8%, respectively, with a median follow-up of 15.3 months in survivors.
  • Eight patients received initial chemotherapy and/or radiation therapy with the intent of performing surgical consolidation.
  • Of the 3 patients who were treated with neoadjuvant therapy (1 with chemotherapy, 1 with radiation, and 1 with chemoradiation) and had surgical consolidation, 2 (67%) were downstaged at cystectomy and remain disease-free.
  • History of superficial transitional cell carcinoma that differentiated into pure SCC (P = .035; hazards ratio [HR] of 3.73) and treatment by radical cystectomy (P = .002; HR of 0.19) were associated with RFS.
  • CONCLUSIONS: In select patients with resectable disease, radical cystectomy remains the mainstay of therapy for pure SCC of the bladder.
  • The role for neoadjuvant therapy is unclear.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Transitional Cell / mortality. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / therapy. Combined Modality Therapy. Cystectomy / methods. Drug Therapy / methods. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy / methods. Survival Rate. Texas. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614317.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


8. Shigehara K, Kitagawa Y, Nakashima T, Shimamura M: Squamous cell carcinoma of the bladder: a patient treated successfully with a new combined chemotherapy regimen, intraarterial nedaplatin and pirarubicin plus intravenous methotrexate and vincristine. Int J Clin Oncol; 2006 Aug;11(4):329-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the bladder: a patient treated successfully with a new combined chemotherapy regimen, intraarterial nedaplatin and pirarubicin plus intravenous methotrexate and vincristine.
  • We report a case of squamous cell carcinoma (SCC) of the bladder treated successfully with intraarterial chemotherapy using nedaplatin.
  • Cystoscopic examination showed tumors on the anterior bladder wall.
  • Computed tomography (CT) scans and magnetic resonance imaging (MRI) revealed extravesical invasion of the tumors, and a clinical diagnosis of T3bN0M0 was made.
  • The patient received a new combined chemotherapy, intraarterial nedaplatin and pirarubicin plus intravenous methotrexate and vincristine.
  • After two courses of the chemotherapy, CT scans and MRI demonstrated no tumor in the bladder.
  • Transurethral bladder-wall biopsy was performed in November 2004, and histopathological examination of the specimen revealed no definite tumors.
  • The patient is alive without evidence of disease more than 1 year after the chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Doxorubicin / analogs & derivatives. Methotrexate / administration & dosage. Organoplatinum Compounds / administration & dosage. Urinary Bladder Neoplasms / drug therapy. Vincristine / administration & dosage
  • [MeSH-minor] Aged. Drug Administration Routes. Female. Humans. Infusions, Intra-Arterial. Injections, Intravenous. Magnetic Resonance Imaging. Neoplasm Invasiveness / diagnostic imaging. Remission Induction / methods. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 2004 Jul;95(5):711-7 [15354717.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;31(3):187-92 [1334448.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Apr;31(4):561-5 [15114700.001]
  • [Cites] Nihon Jibiinkoka Gakkai Kaiho. 2004 Nov;107(11):990-7 [15624504.001]
  • [Cites] Gan To Kagaku Ryoho. 1992 May;19(5):695-701 [1580643.001]
  • [Cites] Eur Urol. 2000 Jan;37(1):85-9 [10671791.001]
  • [Cites] Gan To Kagaku Ryoho. 1992 Apr;19(4):483-8 [1558398.001]
  • [Cites] J Urol. 1995 Nov;154(5):1704-9 [7563327.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;26(6):393-6 [2171794.001]
  • [Cites] Gan To Kagaku Ryoho. 1992 Jun;19(6):871-7 [1605665.001]
  • (PMID = 16937309.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8UQ3W6JXAN / nedaplatin; D58G680W0G / pirarubicin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


9. Shigehara K, Kitagawa Y, Nakashima T, Shimamura M, Katayanagi K, Kurumaya H: [Squamous cell carcinoma of the bladder treated with a new combined chemotherapy regimen, intraarterial nedaplatin and pirarubicin plus intravenous methotrexate and vincristine--second case report in Japan]. Gan To Kagaku Ryoho; 2007 Aug;34(8):1319-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the bladder treated with a new combined chemotherapy regimen, intraarterial nedaplatin and pirarubicin plus intravenous methotrexate and vincristine--second case report in Japan].
  • We report our second patient treated successfully with a new combined chemotherapy regimen of intra-arterial pirarubicin and nedaplatin plus intravenous methotrexate and vincristine for squamous cell carcinoma (SCC) of the bladder.
  • A 57-year-old man consulted our hospital in September 2005 for treatment of bladder tumors diagnosed in another hospital.
  • Magnetic resonance imaging (MRI) showed an extravesical invasive tumor on the anterior wall of the bladder, and clinical stage T2bN0M0 was diagnosed.
  • After he received two courses of this new combined intra-arterial chemotherapy regimen using nedaplatin, tumors were detected in MRI and cystoscopy.
  • There were no severe adverse reactions by this chemotherapy regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Cystectomy. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Drug Administration Routes. Humans. Infusions, Intra-Arterial. Infusions, Intravenous. Male. Methotrexate / administration & dosage. Middle Aged. Organoplatinum Compounds / administration & dosage. Remission Induction. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687223.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8UQ3W6JXAN / nedaplatin; D58G680W0G / pirarubicin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Serretta V, Pomara G, Piazza F, Gange E: Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases. Eur Urol; 2000 Jan;37(1):85-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases.
  • INTRODUCTION: Pure squamous carcinoma (SCC) is a rare entity in western regions.
  • The management of SCC still remains similar to that of transitional carcinoma, although it is a different entity.
  • MATERIAL AND METHODS: Nineteen consecutive cases of pure SCC of the bladder, not related to bilharziasis or spinal cord injury, are herein reported.
  • Involvement of prostatic urethra and upper urinary tract was evident in 9 (47.3%) and 5 patients (26.3%), respectively.
  • Four patients were submitted to neoadjuvant chemotherapy and 1 to presurgical radiotherapy without any objective response.
  • Adjuvant chemotherapy was performed in 3 patients.
  • The possible role of this marker in bladder SCC is discussed.
  • CONCLUSIONS: Invasion of the upper urinary tract and prostatic urethra seems more common in SCC than in transitional cell carcinoma.
  • Preoperative radiotherapy should be considered since pelvic recurrences are the leading cause of progression in squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10671791.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SWITZERLAND
  •  go-up   go-down


11. Wanebo HJ, Begossi G, Belliveau J, Gustafson E: Isolated chemotherapeutic perfusion as neoadjuvant therapy for advanced/unresectable pelvic malignancy. J Clin Oncol; 2009 May 20;27(15_suppl):2555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated chemotherapeutic perfusion as neoadjuvant therapy for advanced/unresectable pelvic malignancy.
  • : 2555 Background: Isolated pelvic perfusion (IPP) provides higher tissue drug levels than high-dose systemic therapy and may enhance resectability and survival in patients failing chemo radiation ± surgery.
  • METHODS: 42 patients had advanced (irradiated) rectal cancer, 8 pts had advanced anorectal cancer, 5 patients had sarcoma.
  • Other cancers included melanoma (M 4pts), endometrial cancer (EC) 2, ovarian cancer (OC) 2, and bladder cancer (BC) 1.
  • Chemotherapy agents included 5FU, (1,500-2,000mg/M<sup>2</sup>), cisplatinum (100mg/M<sup>2</sup>), Oxaliplatin and mitomycin (10-20mg/M<sup>2</sup>) for epithelial cancer and selected agents (Adriamycin, Ifosamide, DTIC, Phenyl Alanine Mustard (PAM) for the remaining tumors: 6 pts received high dose PAM (110/M<sup>2</sup>), Paclitaxel 60mg/m<sup>2</sup> and Cisplatin 150mg/m<sup>2</sup>, 3 required stem cell support (advanced M (1 pt), SCC (1 pt), Endometrial ca (1pt).
  • RESULTS: Palliative IPP for advanced rectal cancer pts provided significant pain control (1-4 months) in 11 of 14 pts with narcotic resistant pain and induced tumor regression in 6 pts.
  • Preoperative perfusion in 26 advanced rectal cancer pts induced a complete path response (in pelvis) in 2 pts and significant regression in 11 pts rendering them resectable.
  • It was 30 months in 8 pts with advanced anorectal squamous cancer (1pt survived >90 mos), 20 months in 4 patients with endometrial/ovarian recurrence, (1 died NED >48 mos), 13 mos in 4 melanoma pts and only 5 months in 5 pts pelvic sarcoma (4-34 mos-NED).
  • CONCLUSIONS: IPP with high dose chemo therapy has promise in palliating or augmenting resectability of advanced pelvic malignancy persisting after conventional surgical and chemoradiation therapy.
  • Stem cell support and biologic therapy merit further exploration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961873.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Taniguchi H, Sakagami J, Suzuki N, Hasegawa H, Shinoda M, Tosa M, Baba T, Yasuda H, Kataoka K, Yoshikawa T: Adenoendocrine cell carcinoma of the gallbladder clinically mimicking squamous cell carcinoma. Int J Clin Oncol; 2009 Apr;14(2):167-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoendocrine cell carcinoma of the gallbladder clinically mimicking squamous cell carcinoma.
  • We present the case of a 62-year-old Japanese man whose histological diagnosis was adenoendocrine cell carcinoma of the gallbladder at autopsy, but whose antemortem diagnosis was squamous cell carcinoma.
  • Abdominal computed tomography revealed a large tumor on the gallbladder involving the adjacent liver, colon, and duodenum, with multiple metastases in the greater omentum and paraportal lymph nodes.
  • The serum level of squamous cell carcinoma antigen (SCCA) was high, whereas that of carbohydrate antigen (CA) 19-9, as well as that of carcinoembryonic antigen (CEA) was within the normal range.
  • Due to these clinical features, we first suspected advanced squamous cell carcinoma of the gallbladder.
  • Though tumor regression was achieved and his serum SCCA level normalized after 3 months, the patient rejected additional chemotherapy and died 8 months after the diagnosis.
  • The histopathological findings made by autopsy demonstrated the tumor to be an adenoendocrine cell carcinoma without squamous carcinoma cells.
  • The case is interesting in that the clinical features were similar to those of squamous cell carcinoma of the gallbladder.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Small Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2001 Jan;98(1):53-7 [11201126.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):355-74 [16139391.001]
  • [Cites] Curr Opin Oncol. 2005 May;17(3):218-24 [15818164.001]
  • [Cites] Tumour Biol. 1998;19(6):488-93 [9817978.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1231-5 [17016656.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1769-74 [15505626.001]
  • [Cites] Surg Today. 2006;36(9):849-52 [16937295.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1493-7 [1516000.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(1):97-101 [10982599.001]
  • [Cites] J Surg Oncol. 2007 Feb 1;95(2):129-34 [17262729.001]
  • [Cites] Int J Cancer. 1991 Feb 1;47(3):376-9 [1704354.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1588-93 [11813580.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):572-80 [17594719.001]
  • [Cites] Jpn J Clin Oncol. 2007 Nov;37(11):843-51 [17942578.001]
  • (PMID = 19390950.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Serpins; 0 / squamous cell carcinoma-related antigen
  •  go-up   go-down


13. González Resina R, Sánchez Bernal ML, Pérez Espejo MP, Rodríguez Corchero FJ, Argüelles Salido E, Campoy Martínez P: [Squamous cell carcinoma of the bladder. Review of our case series]. Arch Esp Urol; 2006 Oct;59(8):785-90
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the bladder. Review of our case series].
  • [Transliterated title] Carcinoma epidermoide vesical. Revisión de nuestra serie.
  • OBJECTIVES: The squamous cell carcinoma of the bladder is a rare tumor in our environment, representing between 1.6-6.7% of all bladder neoplasias.
  • It is more common to find foci of squamous differentiation associated with a transitional cell carcinoma.
  • METHODS: We retrospectively review all squamous cell carcinomas diagnosed and treated in our hospital between 1994 and 2004.
  • We analyze their biological behaviour and the treatment applied.
  • RESULTS: We found 11 cases of squamous cell carcinoma of the bladder, which pathologically were pure squamous cell carcinomas in eight patients and mixed in another three.
  • All of them presented locally advanced tumor stages at the time of diagnosis (> or = T2).
  • Although the treatment of choice is radical cystectomy, it could only be applied in three patients; it was associated with adjuvant chemotherapy in one patient.
  • CONCLUSIONS: The squamous cell carcinoma, in both its forms, pure and mixed, is an aggressive tumor.
  • The late diagnosis of these tumors and their biological behaviour entail a bad prognosis.
  • Only early diagnosis and radical treatment may improve prognosis.
  • [MeSH-major] Carcinoma, Squamous Cell. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17153497.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


14. Black PC, Brown GA, Dinney CP: The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol; 2009 Jan-Feb;27(1):3-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of variant histology on the outcome of bladder cancer treated with curative intent.
  • Patient risk stratification is essential for optimal management of patients with bladder cancer.
  • Risk status determines the application and timing of therapeutic interventions such as repeat transurethral resection, intravesical chemo- and immunotherapy, systemic chemotherapy, and radical cystectomy.
  • One key factor in such risk stratification appears to be the presence of variant histologic patterns in the bladder tumor.
  • More than 90% of tumors are conventional urothelial carcinoma, and the rest consist of urothelial carcinoma with aberrant differentiation (squamous/glandular differentiation, small cell carcinoma, sarcomatoid carcinoma, and micropapillary carcinoma) or nonurothelial carcinoma (squamous cell carcinoma and adenocarcinoma).
  • In this review, we focus on the implications of aberrant differentiation on the management of patients with bladder cancer.
  • All of the variant histologies portend a worse prognosis than pure urothelial carcinoma.
  • Although radical cystectomy remains the mainstay of treatment in all forms of bladder cancer, we highlight the use of neoadjuvant chemotherapy in patients with subtypes responsive to such therapy.
  • [MeSH-major] Medical Oncology / methods. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Algorithms. Carcinoma / pathology. Carcinoma / therapy. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy. Cell Differentiation. Humans. Prognosis. Risk. Sarcoma / pathology. Sarcoma / therapy. Treatment Outcome. Urothelium / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367107.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA91846; United States / PHS HHS / / T32
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


15. Roohullah, Nusrat J, Hamdani SR, Burdy GM, Khurshid A: Cancer urinary bladder--5 year experience at Cenar, Quetta. J Ayub Med Coll Abbottabad; 2001 Apr-Jun;13(2):14-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer urinary bladder--5 year experience at Cenar, Quetta.
  • BACKGROUND: Purpose of this study was to see the incidence, age, sex, geographical distribution, symptoms, personal habits, signs, histo-pathology, early diagnosis and management of cases of Cancer Urinary Bladder (Ca UB) in the patients coming to CENAR, Quetta, Pakistan.
  • 97, in which about 100 cases of cancer of urinary bladder were included, out of which 82 patients were male and 12 were females.
  • RESULTS: During our 5-year period of study, 3571 new cases of cancer were registered at CENAR, out of which 100 (2.8% of total No. of cases) were of Ca UB.
  • Hence 20 new cases of Ca UB per year were registered at CENAR.
  • CONCLUSION: Our study concluded that Ca UB occurs more in male with a male female ratio of 4.5:1 and a high incidence after 40 years of age.
  • Histopathologically, Transitional Cell Carcinoma was dominating (75%).
  • Other histological types seen were squamous cell carcinoma (4%), Adenocarcinoma (3%), UD (5%) and HPNA (10%).
  • The patients were mainly treated with Radiotherapy, because at the time of reporting they were already in stage II or beyond (97%).
  • A few patients (6%) also received chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / epidemiology. Urinary Bladder Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11732213.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


16. Hayashi N, Asano K, Furuta A, Ikemoto I, Kishimoto K, Yamazaki H, Onishi T, Takahashi H, Oishi Y: [Invasive squamous cell carcinoma of the bladder: report of 18 cases and review of literature]. Nihon Hinyokika Gakkai Zasshi; 2004 Jul;95(5):711-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Invasive squamous cell carcinoma of the bladder: report of 18 cases and review of literature].
  • PURPOSE: This study was undertaken to determine the most effective treatment for improvement of the prognosis of patients with squamous cell carcinoma of the bladder (SCC).
  • While clarifying the clinical patterns of these cases, the association between stage, therapy, and prognosis was studied.
  • Of the cases of invasive SCC reported in Japan in the recent 20 years, 54 cases in which the stage, therapy, and prognosis were documented were selected, and the association between the therapy and outcome in each stage was studied.
  • RESULTS: In our series, 11 cases are alive without cancer for over 2 years.
  • Cancer death was experienced in 7 patients.
  • As far as our study of the cases reported in Japan is concerned, the prognosis of the cases having undergone TUR or partial resection of the bladder alone was poor.
  • But, even if patients underwent cystectomy, most of the patients was cancer death in the cases whose cancer was stage III or higher.
  • In the patients receiving some supportive therapy, 4 patients receiving radiation plus cisplatin-based chemotherapy were all alive without for over 2 years.
  • CONCLUSIONS: Total cystectomy is most appropriate as the type of operation for the cases of invasive SCC.
  • But, the cases whose cancer was stage III or higher have high recurrence rate, and must be accompanied with some supportive therapy.
  • We concluded that radiation plus cisplatin-based chemotherapy is a candidate of most effective supportive therapy to improve the prognosis of those patients in the supportive therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15354717.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 21
  •  go-up   go-down


17. Hussain M, Vaishampayan U, Du W, Redman B, Smith DC: Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol; 2001 May 01;19(9):2527-33
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.
  • PURPOSE: To determine the efficacy and toxicity of the drug combination of carboplatin, paclitaxel, and gemcitabine in patients with advanced urothelial carcinoma.
  • PATIENTS AND METHODS: Patients eligible included those with advanced urothelial malignancy of any histology, no previous chemotherapy for metastatic disease, Southwest Oncology Group performance status of 2 or less, serum creatinine levels of 2 mg/dL or less, and adequate bone marrow and hepatic function.
  • Treatment consisted of paclitaxel 200 mg/m2, carboplatin (target area under the curve = 5) on day 1, and gemcitabine 800 mg/m2 on days 1 and 8, repeated every 21 days.
  • Forty-three patients had transitional cell carcinoma, and six had squamous cell carcinoma or mixed histology.
  • Ten patients had metastases to lymph nodes only, six had locally advanced disease, four had locally recurrent disease, 24 patients had visceral metastases, and five had soft tissue metastases.
  • The incidence of febrile neutropenia was 1.4%; no patients died of drug toxicity.
  • The median survival was 14.7 months, with a 1-year survival of 59%.
  • CONCLUSION: Combination paclitaxel, carboplatin, and gemcitabine is active; an encouraging number of patients with advanced urothelial carcinoma treated with this regimen experienced complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urinary Bladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11331332.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5-P30-CA46592-06; United States / NCI NIH HHS / CA / P30-CA22453-20
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


18. Al Meshaan MK, Nayef M, Kwaider T, Otto W, Katchy KC: Peripheral primitive neuroectodermal tumor of the urinary bladder in an Arab woman with history of squamous cell carcinoma: a case report. J Med Case Rep; 2009;3:6840

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral primitive neuroectodermal tumor of the urinary bladder in an Arab woman with history of squamous cell carcinoma: a case report.
  • INTRODUCTION: Peripheral primitive neuroectodermal tumors of the urinary bladder are rare and tend to occur in an older age group than do their counterparts in bones and soft tissue.
  • CASE PRESENTATION: We report a case of peripheral primitive neuroectodermal tumor of the urinary bladder in a 67-year-old woman of Arab origin.
  • She had undergone transurethral resection followed by chemotherapy because of pulmonary metastasized muscle-invasive squamous cell carcinoma of the bladder in 2005.
  • One year later, she first presented with a history of repeated hematuria in our institution.
  • After perforating by transurethral resection partial bladder resection had to be done.
  • Tissue specimen after pathological analysis revealed a peripheral primitive neuroectodermal tumor with tumor cells reactive to cluster of differentiation 99, neuron-specific enolase and S100 protein and stained negative for other markers such as cytokeratins, epithelial membrane antigen, desmin, smooth muscle actin, chromogranin and leucocyte common antigen.
  • Staging computerized tomography was especially free from any hint on organ metastasis, but the patient died due to a cardiac problem only a few months later.
  • CONCLUSIONS: To the best of our knowledge, we report the eighth case of bladder peripheral primitive neuroectodermal tumors in literature and the first concerning an Arab patient.
  • It is also the first presentation of a peripheral primitive neuroectodermal tumor patient with a history of squamous cell carcinoma of the bladder.
  • As in other cases, expression of single-chain-type 1 glycoprotein and neural markers was positive and the disease was at an advanced stage at the time of diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2006 Aug;68(2):257-62 [16904430.001]
  • [Cites] J Clin Pathol. 2006 Jul;59(7):775-8 [16803953.001]
  • [Cites] Int Orthop. 2005 Dec;29(6):406-11 [16200421.001]
  • [Cites] Pathologe. 1998 Feb;19(2):154-8 [9556802.001]
  • [Cites] Histopathology. 2002 Jan;40(1):108-9 [11903609.001]
  • [Cites] Histopathology. 1997 May;30(5):486-90 [9181373.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):2060-5 [3167818.001]
  • [Cites] Pathol Res Pract. 2003;199(11):751-4 [14708642.001]
  • [Cites] Histopathology. 1998 May;32(5):477-8 [9639125.001]
  • (PMID = 19830128.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2726497
  •  go-up   go-down


19. Hussain MH, Glass TR, Forman J, Sakr W, Smith DC, Al-Sarraf M, Jones J, Balcerzak SP, Crawford ED, Grossman HB: Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol; 2001 Jan;165(1):56-60; discussion 60-1
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study.
  • PURPOSE: Patients with locally advanced bladder cancer or who are not medically fit for surgery are a therapeutic dilemma.
  • Radiotherapy with or without single agent cisplatin has been the major therapeutic modality.
  • MATERIALS AND METHODS: Eligible patients had muscle invasive bladder cancer (clinical stages T2-T4) with nodal involvement at or below the level of bifurcation of the iliac vessels, were medically or surgically inoperable, or refused cystectomy.
  • /m.2 daily, 5-fluorouracil on days 1 to 4 and definitive radiotherapy.
  • Chemotherapy was repeated every 28 days, twice during and twice after radiation.
  • Treatment was completed as planned in 32 of 56 (57%) patients.
  • The overall response rate was 51% (95% confidence interval [CI] 37 to 65) based on intent to treat with a complete response rate of 49% (95% CI 35 to 63).
  • CONCLUSIONS: Concurrent 5-fluorouracil, cisplatin and radiation therapy is feasible.
  • Despite a promising complete response rate, the overall 5-year survival suggests the need for more effective systemic therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / mortality. Carcinoma, Transitional Cell / radiotherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Feasibility Studies. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Radiotherapy Dosage. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2001 Jan;165(1):65-6 [11125365.001]
  • (PMID = 11125363.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; etc
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE: Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol; 2004 Jan;171(1):145-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience.
  • PURPOSE: Although rarely curative, chemotherapy remains the mainstay of treatment for metastatic urothelial cancer.
  • The role of surgery for metastatic disease is not well established for urothelial cancer, but is sometimes undertaken in the face of persistent or recurrent disease that can be surgically resected.
  • MATERIALS AND METHODS: We identified 31 patients with metastatic urothelial cancer undergoing metastasectomy with the intent of rendering them free of disease.
  • RESULTS: Median survival from diagnosis of metastases and from time of metastasectomy was 31 and 23 months, respectively.
  • Median time to progression following metastasectomy was 7 months.
  • CONCLUSIONS: The results in this highly selected cohort, with 33% alive at 5 years after metastasectomy, suggest that resection of metastatic disease is feasible and may contribute to long-term disease control especially when integrated with chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14665863.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50-CA91846
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


21. Ishii N, Yonese J, Tsukamoto T, Maezawa T, Fukui I, Ishikawa Y, Aoki N: [Multiple synchronous primary malignant tumors of fibrosarcoma and squamous cell carcinoma in the urinary bladder: a case report]. Nihon Hinyokika Gakkai Zasshi; 2002 Jul;93(5):642-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple synchronous primary malignant tumors of fibrosarcoma and squamous cell carcinoma in the urinary bladder: a case report].
  • A 65-year-old housewife presented with a diagnosis of malignant spindle cell tumor of the bladder which had been diagnosed by work up for chance hematuria.
  • Urine cytology revealed a small number of squamous epithelial cells showing dyskeratosis but no spindle cells.
  • Computed tomography and magnetic resonance images showed a markedly enhanced mass, 4 cm in diameter, on the anterior wall of the urinary bladder, which appeared to be adhesive to the pubic bone.
  • Under the suspicion of sarcoma of the urinary bladder, we performed anterior pelvic exenteration with construction of an ileal conduit.
  • Although the anterior wall of the urinary bladder was mildly adhesive to the pubic bone, the surgical margin was negative for malignant cells.
  • The tumor corresponded to a fibrosarcoma that infiltrated the adipose tissue surrounding the urinary bladder.
  • The entire mucosa of the bladder showed diffuse squamous metaplasia, and well differentiated squamous cell carcinoma with pearl formation was found in part.
  • These two malignant tumors were clearly apart from each other, resulting in the histologic diagnosis of synchronous multiple malignant tumors of the bladder.
  • The patient developed a local relapse and pulmonary metastasis of fibrosarcoma one month postoperatively and died two month later without any response to chemotherapy (CYVADIC) and radiotherapy.
  • The current case seems to be the first one in Japan (third in the world) of a patient with multiple synchronous primary malignant tumors, carcinoma and sarcoma, airsing in the urinary bladder.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Fibrosarcoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174642.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 12
  •  go-up   go-down


22. Filov VA, Reztsova VV, Kil'maeva NE, Petukhov DV, Pinchuk BT: [An experimental study of the antitumor properties of olipifat]. Vopr Onkol; 2000;46(3):332-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Olipiphat is an original lignin-based mix developed by special technology.
  • It showed antitumor action against carcinoma of Ehrlich, breast adenocarcinoma Ca 755, melanoma B 16, lung carcinoma of Lewis, lymphosarcoma of Pliss, Walker's carcinoma, sarcoma 45 (tumor growth inhibition by 83-92%, increase in survival by 42-54%) and spontaneous murine tumors (the total of 9 pathologies).
  • The drug was administered by 3-5 injections at 2-3 day intervals.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lignin / analogs & derivatives. Lignin / therapeutic use. Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Benzopyrenes. Carcinoma, Squamous Cell. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Female. Humans. Mice. Mice, Inbred Strains. Mouth Neoplasms. Neoplasm Transplantation. Rats. Time Factors. Tumor Cells, Cultured / drug effects. Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10976281.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] RUSSIA
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzopyrenes; 0 / olipifat; 9005-53-2 / Lignin
  •  go-up   go-down


23. Molteni A, Ward WF, Ts'ao CH, Taylor J, Small W Jr, Brizio-Molteni L, Veno PA: Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Curr Pharm Des; 2003;9(9):751-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists.
  • Angiotensin converting enzyme (ACE) inhibitors and angiotensin II (AII) type 1 receptor antagonists have strong cytostatic properties on in vitro cultures of many normal and neoplastic cells.
  • They are effective, in particular, in reducing the growth of human lung fibroblasts, renal canine epithelial cells, bovine adrenal endothelial cells, simian T lymphocytes, and of neoplastic cell lines derived from human neuroblastomas, a ductal pancreatic carcinoma of the Syrian hamsters, human salivary glands adenocarcinomas, and two lines of human breast adenocarcinomas.
  • ACE inhibitors are also effective in protecting lungs, kidneys and bladders from the development of nephropathy, pneumopathy, cystitis, and eventually fibrosis in different models of organ-induced damage such as exposure to radiation, chronic hypoxia, administration of the alkaloid monocrotaline or bladder ligation.
  • ACE inhibitors and AII type 1 receptor antagonists are also effective in reducing excessive vascular neoformation in a model of injury to the cornea of rats and rabbits, and in controlling the excessive angiogenesis observed in the Solt-Farber model of experimentally induced hepatoma, in methylcholantrene or radiation-induced fibrosarcomas, in radiation-induced squamous cell carcinomas and in the MA-16 viral-induced mammary carcinoma of the mouse.
  • The mitogenic effect of AII is well established and a reduction of AII synthesis may well explain cell and neoplasm delayed growth.
  • Moreover, AII regulates and enhances the activity of several growth factors including transforming growth factor B (TGFB) and smooth muscle actin (SMA); and many of these factors are reduced in tissues of animals treated with ACE inhibitors and AII type 1 receptor antagonists.
  • The ACE inhibitors containing a sulphydril (SH) or thiol radical in their moiety (Captopril and CL242817) seemed to be more effective in controlling fibrosis and the growth of some neoplastic cells than those ACE inhibitors without this thiol radical in their structure, even if the second group of these drugs show in vitro a stronger inhibitory effect on converting enzyme activity.
  • However, although these additional properties are pharmacologically relevant, the blockade of AII synthesis plays an essential role in the cytostatic activity of these two categories of drugs.
  • These observations underline that in addition to the beneficial effect of these drugs on the cardiovascular system, new potential applications are opening for their wider deployment.
  • [MeSH-minor] Animals. Humans. Neoplasms / drug therapy. Neoplasms / metabolism. Receptors, Angiotensin / physiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12570792.001).
  • [ISSN] 1381-6128
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 24652; United States / NCI NIH HHS / CA / CA 52750; United States / NCI NIH HHS / CA / CA 64239; United States / NIDDK NIH HHS / DK / DK 15612; United States / NHLBI NIH HHS / HL / HL 25106
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiotensin Receptor Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Antineoplastic Agents; 0 / Receptors, Angiotensin
  • [Number-of-references] 70
  •  go-up   go-down


24. Zwecker M, Daich A, Blumen N, Zeilig G, Ohry A: Slow ascending myelopathy, tetraplegia, carcinoma of the bladder and amyloidosis in a patient with ankylosing spondylitis. Spinal Cord; 2000 May;38(5):327-9
MedlinePlus Health Information. consumer health - Spinal Cord Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Slow ascending myelopathy, tetraplegia, carcinoma of the bladder and amyloidosis in a patient with ankylosing spondylitis.
  • DESIGN: Case report of a 60-year-old patient suffering from AS, who developed over a period of 39 years a slow ascending myelopathy leading to tetraplegia, squamous cell carcinoma of the bladder and amyloidosis of the small intestine secondary to neuropathic bladder and bowel.
  • Neurogenic bladder and bowel complicated to squamous cell carcinoma and amyloidosis.
  • [MeSH-major] Amyloidosis / complications. Carcinoma / complications. Quadriplegia / etiology. Spinal Cord Diseases / etiology. Spondylitis, Ankylosing / complications. Urinary Bladder Neoplasms / complications
  • [MeSH-minor] Follow-Up Studies. Humans. Intestinal Diseases / drug therapy. Male. Middle Aged. Muscle Hypotonia / etiology. Urinary Bladder, Neurogenic / etiology






Advertisement